Therefore, therapeutic agents which disrupt resistance to conventional anticancer therapy, such as PARP inhibitors, might be beneficial in the treatment of the poor prognostic subgroup of gallbladder carcinoma with high expression of FAM83H/ZNF16 [33–35]. The gene discussed is ZNF16; the disease is gallbladder carcinoma.